Publications by authors named "M P Stylianou"
Article Synopsis
- The study reviews the 24-hour movement behaviors of LGBTQA+ young people, highlighting significant health challenges they face compared to general population guidelines.
- Fifty-six studies were analyzed, revealing that LGBTQA+ individuals are less likely to meet both physical activity and sleep guidelines, particularly among children and adolescents.
- The findings suggest a need for better measurement tools and more focus on improving sleep and reducing sedentary behavior in LGBTQA+ youth.
Rationale and design of the randomized COmparison of Methods for Pulmonary blood flow Augmentation: Shunt versus Stent (COMPASS) trial: A Pediatric Heart Network study.
Christopher J Petit Jennifer C Romano Jeffrey D Zampi Sara K Pasquali Courtney E McCracken Mario Stylianou
Catheter Cardiovasc Interv
October 2024
Neonates with congenital heart disease (CHD) and ductal-dependent pulmonary blood flow (DD-PBF) require early intervention. Historically, this intervention was most often a surgical systemic-to-pulmonary shunt (SPS; e.g.
View Article and Find Full Text PDFRationale and Design of the Randomized COmparison of Methods for Pulmonary Blood Flow Augmentation: Shunt Versus Stent (COMPASS) Trial: A Pediatric Heart Network Study.
Christopher J Petit Jennifer C Romano Jeffrey D Zampi Sara K Pasquali Courtney E McCracken Mario Stylianou
World J Pediatr Congenit Heart Surg
November 2024
Neonates with congenital heart disease and ductal-dependent pulmonary blood flow (DD-PBF) require early intervention. Historically, this intervention was most often a surgical systemic-to-pulmonary shunt (SPS; eg, Blalock-Thomas-Taussig shunt). However, over the past two decades, an alternative to SPS has emerged in the form of transcatheter ductal artery stenting (DAS).
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to replicate a previous finding that EDTA-based chelation therapy reduces cardiovascular disease (CVD) events in individuals with diabetes and a history of myocardial infarction (MI).
- - Conducted at 88 sites in the US and Canada, the trial involved 959 participants who were randomly assigned to receive either chelation therapy or a placebo, with a median follow-up of 48 months.
- - Results showed no significant difference in CVD events between the chelation group (35.6% experienced a primary event) and the placebo group (35.7%), indicating that chelation may not provide the hoped-for benefits in this population.